Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 1, 2000, Pages 14-21

  Krause, Dietmar ^a   Schleusser, Barbara ^a   Herborn, Gertraud ^a   Rau, Rolf ^a,b  

^a Evangelisches Fach krankenhaus Ratingen   (Germany)

^b Evangelisches Fachkrankenhaus R ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE EXPECTANCY; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034083138     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7     Document Type: Article

References (46)

1. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-82.
2. Kremer JM, Phelps CT. Long-term prospective study in the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
3. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992;35:129-37.
4. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994;37: 1492-8.
5. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures J-P. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 1991;18: 1323-7.
6. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
7. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
8. Bologna C, Viu P, Picot M-C, Jorgensen C, Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997;36:535-40.
9. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953;249:553-6.
10. Duthie JJR, Brown PE, Truelove LH, Baragar FD, Lawrie AJ. Course and prognosis in rheumatoid arthritis: a further report. Ann Rheum Dis 1964;23:193-204.
11. Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum 1970;13:125-30.
12. Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 1976;29:459-67.
13. Mutru O, Laakso M, Isomaki HA, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ 1985;290:1797-9.
14. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982;11:81-6.
15. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25 year prospective follow-up. J Rheumatol 1984;11:158-61.
16. Ehrhardt CC, Mumford PA, Venables PRW, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989;48:7-13.
17. Jacoby RK, Jayson MIV, Cosh JA. Onset, early stages and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11 year follow-up. BMJ 1973;278:96-100.
18. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a 15 year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984;3:11-20.
19. Cosh JA, Rasker JJ. A 20 year follow-up study of 100 patients with rheumatoid arthritis [letter]. Ann Rheum Dis 1982;41:317.
20. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
21. Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
22. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
23. Weinblatt ME, Coblyn JS, Fox DA, Fraser DA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
24. Rau R, Herborn G, Karger T, Werdier D. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy: a controlled study. Arthritis Rheum 1991;34:1236-44.
25. Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-9.
26. Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 1998;25:1485-92.
27. Ropes MW, Bennett GA, Cobb S, Jacox RF, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
29. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
30. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
31. Van der Veen MJ, van der Heijde A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53: 224-8.
32. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder JJ, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
33. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
34. Symmons DE. Excess mortality in rheumatoid arthritis - is it the disease or the drug? J Rheumatol 1995;22:2200-1.
35. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14:240-51.
36. Söderlin MK, Nieminen P, Hakala M. Functional status predicts mortality in a community based rheumatoid arthritis population. J Rheumatol 1998;25:1895-9.
37. Allebeck P, Rodvall Y, Allander E. Mortality in rheumatoid arthritis, particularly as regards drug use. Scand J Rheumatol 1985;14:102-8.
38. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990;49:363-9.
39. Kazis LE, Anderson JJ, Meenan RF. Health status as a predictor of mortality in rheumatoid arthritis: a five-year study. J Rheumatol 1990;17:609-13.
40. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989;79 Suppl: 67-95.
41. Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989;48:7-13.
42. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;337:1108-11.
43. Rasker JJ, Cosh JA. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 1981; 40:115-20.
44. Isomäki HA. Mortality in patients with rheumatoid arthritis. In: Wolfe F, Pincus T, editors. Rheumatoid arthritis. New York: Marcel Dekker; 1994. p. 235-46.
45. Myllykangas-Luosujärwi R, Aho K, Isomäki H. Deaths attributed to anti-rheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995;22:2214-7.
46. Lehtinen K, Isomäki H. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991;18:524-9.